Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100OW0Q
Period2021-10-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Revenue¥36.2bn2020-10-01 → 2021-09-30Cons.Net sales (5-year summary)
Revenue¥27.2bn2020-10-01 → 2021-06-30Cons.Net sales
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Operating income¥572m2020-10-01 → 2021-06-30Cons.Operating income
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥759m2020-10-01 → 2021-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥608m2020-10-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥612m2020-10-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥517m2020-10-01 → 2021-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥428m2020-10-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Net income¥446m2020-10-01 → 2021-06-30Cons.Profit loss
Total assets¥15.0bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2021-09-30Cons.Assets
Total assets¥16.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥8.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.8bnat 2021-09-30Cons.Liabilities
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥799mat 2021-09-30Cons.Cash and deposits
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥564.912020-10-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥467.382020-10-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.172021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn
Otherother segmentsrevenue2020-10-01 → 2021-06-30¥331m
Otherother segmentsrevenue external2020-10-01 → 2021-06-30¥331m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2020-10-01 → 2021-06-30¥10.9bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2020-10-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2020-10-01 → 2021-06-30¥27.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-10-01 → 2021-06-30¥27.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Remeasurements of defined benefit plansPrior1YearInstant-4551000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-3867000JPY
Valuation and translation adjustmentsPrior1YearInstant767011000JPY
Valuation and translation adjustmentsCurrentQuarterInstant580981000JPY
Non controlling interestsPrior1YearInstant52724000JPY
Non controlling interestsCurrentQuarterInstant72527000JPY
Net assetsPrior1YearInstant6281712000JPY
Net assetsCurrentQuarterInstant6561684000JPY
Liabilities and net assetsPrior1YearInstant16128570000JPY
Liabilities and net assetsCurrentQuarterInstant15032596000JPY
Net salesPrior1YTDDuration27204004000JPY
Net salesCurrentYTDDuration27901693000JPY
Cost of salesPrior1YTDDuration24869424000JPY
Cost of salesCurrentYTDDuration25319443000JPY
Gross profitPrior1YTDDuration2334579000JPY
Gross profitCurrentYTDDuration2582250000JPY
Selling general and administrative expensesPrior1YTDDuration1762627000JPY
Selling general and administrative expensesCurrentYTDDuration1818758000JPY
Operating incomePrior1YTDDuration571951000JPY
Operating incomeCurrentYTDDuration763491000JPY
Interest income noiPrior1YTDDuration2242000JPY
Interest income noiCurrentYTDDuration2295000JPY
Dividends income noiPrior1YTDDuration26167000JPY
Dividends income noiCurrentYTDDuration34559000JPY
Commission fee noiPrior1YTDDuration6829000JPY
Commission fee noiCurrentYTDDuration6895000JPY
Other noiPrior1YTDDuration5317000JPY
Other noiCurrentYTDDuration10954000JPY
Non operating incomePrior1YTDDuration40557000JPY
Non operating incomeCurrentYTDDuration54705000JPY
Interest expenses noePrior1YTDDuration739000JPY
Interest expenses noeCurrentYTDDuration1318000JPY
Commission fee noePrior1YTDDuration1902000JPY
Commission fee noeCurrentYTDDuration2244000JPY
Other noePrior1YTDDuration1662000JPY
Other noeCurrentYTDDuration447000JPY
Non operating expensesPrior1YTDDuration4304000JPY
Non operating expensesCurrentYTDDuration4010000JPY
Ordinary incomePrior1YTDDuration608204000JPY
Ordinary incomeCurrentYTDDuration814187000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration26000JPY
Gain on sales of investment securities eiPrior1YTDDuration13332000JPY
Gain on sales of investment securities eiCurrentYTDDuration206000JPY
Gain on investments in partnership eiPrior1YTDDuration12036000JPY
Gain on investments in partnership eiCurrentYTDDuration1446000JPY
Extraordinary incomePrior1YTDDuration25369000JPY
Extraordinary incomeCurrentYTDDuration1679000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration81000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration114000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-09-30pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-09-30pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2020-10-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2020-10-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass